Adverse Events in the New Age of Front-line Combination Approaches in Advanced Gynecologic Cancers

Statement of Need

Immune checkpoint inhibitors (ICIs), PARP inhibitors, VEGF inhibitors, kinase inhibitors, and chemotherapy are all being used in various combinations for the treatment of endometrial and ovarian cancers. As these new combinations seek to further improve and enhance the efficacy of treatment, the risk of AEs increases. During this informational podcast, Dr. Richard Penson, Dr. David O’Malley, and Ms. Jennifer Filipi will educate clinicians on the prevention, mitigation, and management of AEs that arise from these new combination regimens.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

Implement best multidisciplinary practices in the early mitigation and management of AEs of new and emerging first-line therapeutic approaches for gynecologic cancers.

Financial Support

Supported by a joint educational grant from AstraZeneca Pharmaceuticals and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Target Audience

Primary Audiences: Medical oncologists, gynecologic oncologists, physician assistants (PAs), nurses, nurse practitioners (NPs), and pharmacists working in oncology settings
Secondary Audiences: Gynecologists and primary care physicians (PCPs)

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional (IPCE) 0.5

This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education Credit for learning and change.

Physicians (ACCME) 0.5

CME Outfitters, LLC, designates this Enduring Material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 0.5

This activity is designated for 0.50 contact hours.

California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology

Pharmacists (ACPE) 0.5

This application-based activity is approved for 0.50 contact hours ( 0.05 CEUs) of continuing pharmacy credit (JA0007185-0000-24-014-H01-P).

PAs (AAPA) 0.5

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until 04/30/2025. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 0.5

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

Dr. Penson reports the following financial relationships:

Advisory Board: Aadi Bioscience; AstraZeneca; GSK; ImmunoGen, Inc.; Merck & Co., Inc.; Mersana Therapeutics, Inc.; Novacure; Roche; Sutro Biopharma, Inc.; and Vascular Biogenics

Consultant: Serves on DSMBs for AstraZeneca; EQRx; and Roche

Research Support: Intuitional research funding (as PI) for Array BioPharma Inc.; AstraZeneca; Eisai Inc.; Genentech, Inc.; and Vascular Biogenics

Other financial or material support: Royalties: BMJ Publishing Group Ltd; Elsevier; UpToDate, Inc.; Wolters Kluwer Health and Wiley-Blackwell. Payment for educational events: Research to Practice; ExpertConnect; and ReachMD

Ms. Filipi has no financial relationships to disclose.

Dr. O’Malley reports the following financial relationships:

Advisory Board/Consultant: AbbVie Inc.; Adaptimmune; Agenus Inc.; Arquer Diagnostics; Arcus Biosciences, Inc.; AstraZeneca; Atossa Therapeutics, Inc.; Boston Biomedical, Inc.; Cardiff Oncology, Inc.; Celcuity, Inc.; Clovis Oncology; Corcept Therapeutics; Duality Biologics; Eisai Inc.; Elevar Therapeutics; Exelisis, Inc.; F. Hoffmann-La Roche Ltd.; Genentech, Inc.; Genelux Corporation; GSK; GOG Foundation Inc.; ImmunoGen, Inc.; Imvax, Inc.; InterVenn Biosciences; InxMed; Iovance Biotherapeutics, Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Laekna Therapeutics; Leap Therapeutics, Inc.; Luzsana Biotechnology, Inc.; Merck & Co., Inc.; Merck Sharp & Dohme Corp.; Mersana Therapeutics, Inc.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Novocure; OncoC4; Onconova Therapeutics; Regeneron Pharmaceuticals, Inc.; Repimmune Group Inc.; R-Pharm-US LLC; Roche Diagnostics; Seattle Genetics, Inc./Seagen Inc.; Sorrento Therapeutics, Inc.; Sutro Biopharma, Inc.; Tarveda Therapeutics; Toray; Trillium Therapeutics Inc.; Umoja Biopharma; Verastem, Inc.; VBL Therapeutics; Vincerx Pharma; Xencor; and Zentalis Pharmaceuticals

Grants/Research Support: AbbVie Inc.; Advaxis, Inc.; Agenus Inc.; Alkermes; Aravive Inc.; Arcus Biosciences, Inc.; AstraZeneca; BeiGene, Inc.; Boston Biomedical, Inc.; Bristol Myers Squibb Company; Clovis Oncology; Deciphera Pharmaceuticals, Inc.; Eisai Inc.; EMD Serono, Inc.; Exelixis, Inc.; Genentech, Inc; Genmab; GSK; GOG Foundation Inc.; Hoffmann-La Roche Inc.; ImmunoGen, Inc.; Incyte; Iovance Biotherapeutics, Inc.; Karyopharm; Leap Therapeutics, Inc.; Ludwig Institute for Cancer Research; Merck & Co., Inc.; Merck Sharp & Dohme Corp.; Mersana Therapeutics, Inc.; National Cancer Institute (NCI); Novartis ; NovoCure; NRG Oncology; OncoC4; OncoQuest Pharmaceuticals Inc.; Pfizer Inc.; Precision Therapeutics, Inc.; Prelude Therapeutics; Regeneron Pharmaceuticals, Inc; RTOG; Rubius Therapeutics; Seattle Genetics, Inc./Seagen Inc.; Sutro Biopharma, Inc.; SWOG Cancer Research Network; Tesaro, Inc.; and Verastem, Inc

The following individuals have no financial relationships to disclose:

Alaa Bawaneh, MD, PhD (Peer Reviewer)
Andrea Edwards, PA-C (Peer Reviewer)
Thomas Mitchell (Planning Committee)
David Modrak, PhD (Planning Committee)
Susan H. Yarbrough, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

PD-103-043024-90

Adverse Events in the New Age of Front-line Combination Approaches in Advanced Gynecologic Cancers

Faculty

Statement of Need

Learning Objectives

Financial Support

Target Audience